Abstract 857
Background
Colonoscopy is recommended as preferred test for first-degree relatives (FDRs) of colorectal cancer (CRC) patients. However, colonoscopy screening rate remains low. A systematic review and meta-analysis conducted by the research team show that tailored communication is an effective approach to increase uptake of colonoscopy. However, the decision rules that guide the tailored process remain unclear. Based on the identified evidences, a mHealth intervention with an integrated tailoring decision system was developed. This study aimed to test the feasibility and acceptability of this mHealth intervention in Chinese FDRs.
Methods
A single-blinded, family-based cluster randomized controlled trial was conducted. 20 families with CRC patients were randomized to intervention (10 families, n = 11) or control group (10 families, n = 10). Intervention consists of 3 sessions that provided tailored cancer and screening messages on response of personal assessment. All participants received an e-brochure on CRC and CRC screening. Feasibility was measured by recruitment and completion rate, whereas acceptability was assessed by a self-developed questionnaire.
Results
34.5% of eligible family members agreed to participate. 70% of participants completed the trial and all of them completed 3 sessions. All the participants satisfied with the intervention, and agreed the intervention help them understand their risks and appropriate screening recommendations. The main reason for low recruitment rate is that cancer cases were contacted through phone to identify FDRs. Even this is a common strategy when conducting family trials, it is difficult to obtain the trust of FDRs by phone due to the adverse influence of phone scam.
Conclusions
It is acceptable to provide mHealth intervention to Chinese FDRs. However, family recruitment utilizing cancer registry-identified cases seems less feasible in Chinese population. Recruitment through direct contact with FDRs is recommended, for example, through current screening program or clinical units. Furthermore, a definitive trial to test the effectiveness of developed intervention is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bai Yang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract